CEPA Archives - Focal Point https://focalpointresearch.net/tag/cepa/ Scientific, Regulatory and New Product Consultants Mon, 13 Apr 2026 18:18:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://focalpointresearch.net/wp-content/uploads/2021/11/cropped-focal_point_chart_03-32x32.jpg CEPA Archives - Focal Point https://focalpointresearch.net/tag/cepa/ 32 32 126679100 New SNAc provisions added for two substances on Canada’s DSL https://focalpointresearch.net/canadian-quality-assurance/new-snac-provisions-added-for-two-substances-on-canadas-dsl/ Mon, 13 Apr 2026 18:18:38 +0000 https://focalpointresearch.net/?p=5829 ECCC and Health Canada have announced updates to the DSL in Canada Gazette, Part I, introducing Significant New Activity (SNAc) provisions for two substances used in consumer products, including cosmetics: 2-ethylhexyl 2-ethylhexanoate and Cyclohexylamine. The new provisions require companies to submit data for new activities involving these substances at quantities as low as 0.1% in […]

The post New SNAc provisions added for two substances on Canada’s DSL appeared first on Focal Point.

]]> ECCC and Health Canada have announced updates to the DSL in Canada Gazette, Part I, introducing Significant New Activity (SNAc) provisions for two substances used in consumer products, including cosmetics: 2-ethylhexyl 2-ethylhexanoate and Cyclohexylamine. The new provisions require companies to submit data for new activities involving these substances at quantities as low as 0.1% in products, with data requirements that exceed those outlined in Schedule 4 of the New Substances Notification (NSN) Regulations. Companies are advised to review their current and planned uses of these substances to ensure the necessary data are available to meet the SNAc requirements.

Should you identify these two ingredients in your formulations and would like further information on next steps, please contact us.

The post New SNAc provisions added for two substances on Canada’s DSL appeared first on Focal Point.

]]> 5829 Revised In-Commerce List (R-ICL) Update https://focalpointresearch.net/canadian-regulatory/revised-in-commerce-list-revised/ Thu, 11 Apr 2019 14:30:57 +0000 https://www.focalpointresearch.net/?p=4382 What is the R-ICL? The Canadian Environmental Protection Act, 1999 (CEPA, 1999) was implemented by Health Canada to protect the environment and human health by contributing towards sustainable development. A section of the Act focuses on decreasing the risks associated with new and existing substances. Substance lists were established to distinguish new substances from existing […]

The post Revised In-Commerce List (R-ICL) Update appeared first on Focal Point.

]]> What is the R-ICL?

The Canadian Environmental Protection Act, 1999 (CEPA, 1999) was implemented by Health Canada to protect the environment and human health by contributing towards sustainable development. A section of the Act focuses on decreasing the risks associated with new and existing substances. Substance lists were established to distinguish new substances from existing ones, and to determine reporting requirements or risk assessments needed for certain substances.

The In-Commerce List is an administrative list created for substances regulated under the Food and Drugs Act (FDA) that had been subject to the New Substances Notification Regulations (NSNR) and CEPA 1999 in September 2001. The Revised In-Commerce List (R-ICL) was created to address necessary concerns of substance duplications, omissions, and inaccuracies that were on the In-Commerce List.

Recent News Updates:

One year following a final notice published in the Canada Gazette Part I in November 2018, nomination of substances to the Revised In-Commerce List will close on November 3rd, 2019. Of the substances that are regulated under the Food and Drugs Act, substances that are no longer in commerce will likely be removed from the R-ICL in future updates.

The following 20 pharmaceutical ingredients were under review in 2017-2018 as higher priority substances with potential risk to human health: Alendronate sodium and Alendronic acid; Modafinil; Divalproex sodium; Gliclazide; Gabapentin; Lamotrigine; Sucralfate; Celecoxib; Ephedrine, Ephedrine dl-, and Ephedrine sulfate; Entacapone; Atomoxetine hydrochloride; Atovaquinone; Bupropion hydrochloride; Cefazolin sodium; Oxcarbazepine; Acebutolol hydrochloride; Domperidone, Domperidone maleate; Lopinavir; Telmisartan; Olanzapine.

The assessment reports for these 20 ingredients are scheduled to be published in 2020/2021. Post 2020, HC aims to retire the R-ICL list by publishing rapid screening documents for low-priority/low volume substances and bringing feasible substances into compliance with CEPA regulations to be incorporated into the Domestic Substances List (DSL). Non-response to Section 71 substances will result in removal from the R-ICL.

For more information, please contact Focal Point Research Inc.  We are leading North American Regulatory and New Product Consultants for Medical Devices, Natural Health Products, OTC Drugs, Cosmetics, and other consumer products regulated by Health Canada and the U.S. FDA.

The post Revised In-Commerce List (R-ICL) Update appeared first on Focal Point.

]]> 4382